Opendata, web and dolomites

AGLYC

The First In Vitro Diagnostic Device for the Early Detection of Cardiac Ischemia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AGLYC project word cloud

Explore the words cloud of the AGLYC project. It provides you a very rough idea of what is the project "AGLYC" about.

cvd    detection    care    obviously    stage    cagr    diagnosis    84    jobs    company    accounting    useless    reversible    36m    estimate    accounted    hrs    sublicense    don    necrosis    diagnostics    pharmaceutical    fact    tissue    stratification    commercialization    diseases    31    rapid    biomarkers    plasma    almost    usa5eu    tissues       restriction    ischemic    poc    women    103m    2017    onset    detects    medtech    cardiac    ebitda    either    2023    patients    aglyc    globe    smei    shortage    model    small    diagnostic    19m    medical    risk    advantages    completion    vitro    detecting    supply    heart    levels    damage    gt    biomarker    markers    sensitivity    2016    2024    90    market    97    right    successful    lab    min    647m    demonstrates    61    39    device    man    glyc    business    70m    trl6    cardiovascular    progression    apo    sublicensed    prevent    deaths    ivd    irreversible    morbidity    global    effectiveness    detect    ischemia    glycardial    blood    causing    circulating    2015    quantification    point    organ    oxygen    competitive    co    prognosis    death   

Project "AGLYC" data sheet

The following table provides information about the project.

Coordinator
GLYCARDIAL DIAGNOSTICS, SL 

Organization address
address: CALLE BALDIRI REIXAC 48 - PLANTA 1 PUERTA B04 PARC CIENTIFIC DE BARCELONA TORRE R
city: BARCELONA
postcode: 8028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.glycardial.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-07-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLYCARDIAL DIAGNOSTICS, SL ES (BARCELONA) coordinator 50˙000.00

Map

 Project objective

Cardiovascular diseases (CVD) are the leading cause of death/morbidity across the globe, accounting for 31% of all deaths in 2015. Early detection of ischemia (restriction in blood supply to tissues, causing oxygen shortage) is essential to prevent the progression of heart damage, but right now, we don’t have any biomarkers for the early detection of cardiac ischemia. In fact, almost 90% of the available in vitro diagnostic (IVD) methods are based on the quantification of markers of necrosis, an advanced stage of organ damage. Obviously, these methods are useless for the early detection of ischemic damage.

AGLYC is an IVD device based on the rapid quantification circulating plasma Apo J-Glyc levels as a novel biomarker for the diagnosis, prognosis and risk stratification of ischemia and ischemic tissue damage. AGLYC demonstrates a 97% sensitivity in detecting the presence of cardiac ischemia; market state of the art is 39%. It also detects ischemic damage at an early and reversible phase (30 min after ischemia onset); state of the art can only detect ischemia 6 hrs after its onset when tissue damage is irreversible. We are currently at TRL6 having the competitive advantages of high sensitivity, early detection and cost effectiveness.

The Global IVD market accounted for $61,103M in 2016 and is estimated to reach $84,647M by 2023, growing at a CAGR of 4.6% from 2017-2023. We have estimated a lab-based target market of >70M patients (USA5EU) and a Point of Care (POC) target market of >36M patients (USA5EU). Our main business model will be a sublicense model: a lab-based test will be developed and sublicensed to either a medical device company (like MedTech) or to a pharmaceutical company for the co-development and commercialization of the POC device. GlyCardial Diagnostics, S.L. is a small company of 4 (3 women, 1 man) but with the successful completion of the SMEI Phase 1 and 2 we estimate an EBITDA of around €19M, creating 10 new jobs by 2024.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AGLYC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AGLYC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Project Tracworx (2019)

Tracworx is a data analytics tool that allows you to establish bottlenecks in your patient flow, while understanding your efficiencies and ultimately your true capacity.

Read More  

Manuback (2019)

MANUBACK, the smart garment for operator protection in the field of Manual Handling of Goods

Read More  

TalentVision (2019)

INSIGHTS FOR TALENT ASSESSMENT USING COMPUTER VISION TECHNIQUES FROM NEURO PSYCHOLOGY

Read More